功能性多巴胺能闪烁显像在路易体痴呆诊断中的诊断效能:一项更新的系统评价
本项更新的系统评价依据PRISMA指南检索PubMed/MEDLINE、EMBASE和Cochrane Library截至2022年6月的文献,定性分析59项研究。结果显示多巴胺转运体显像在路易体痴呆诊断中起重要作用,123I-FP-CIT为最常用放射性配体(54项研究,91.5%),图像分析以半定量分析为主(29项研究,49%),目前尚无研究采用定量分析方法测量多巴胺转运体丢失。
要点
- 多巴胺转运体显像在路易体痴呆评估中起重要作用
- 123I-FP-CIT为最常用放射性配体,见于54项研究(91.5%)
- 图像分析以半定量分析为主(29项研究,49%),尚无研究采用定量分析方法
核心结论
- 本系统评价证实多巴胺能闪烁显像在路易体痴呆评估中起重要作用。
- 通过多巴胺能闪烁显像识别路易体痴呆前驱期并结合对临床神经精神症状的重视,可能有助于早期诊断。
- 多数已发表研究采用半定量分析评估示踪剂摄取,目前尚无研究采用定量分析方法测量多巴胺转运体丢失。
- 纯定量方法能否更准确地评估多巴胺能传递的优越性需进一步明确。
研究设计与样本
- 本系统评价按照PRISMA指南开展。
- 检索PubMed/MEDLINE、EMBASE和Cochrane Library数据库截至2022年6月发表的研究。
- 使用QUADAS-2工具评估研究的偏倚风险和适用性担忧。
- 对59项研究进行定性分析。
主要发现
- 59项研究中,19项(32%)探讨多巴胺转运体显像的诊断效能。
- 15项(25%)评估在路易体疾病谱中识别路易体痴呆。
- 18项(31%)研究功能性多巴胺能显像在区分路易体痴呆与其他痴呆中的作用。
- 19项研究(32%)显示多巴胺转运体丢失与临床结局相关。
- 15项研究(25%)显示多巴胺转运体丢失与其他功能显像模态相关。
关键数值与推荐
- 各研究使用多种放射性配体,技术方面存在异质性,最常用者为[123I]N-ω-氟丙基-2β-甲氧羰基-3β-(4-碘苯基)去甲托烷(123I-FP-CIT),见于54项研究(91.5%)。
- 图像分析采用视觉分析(9项研究,15%)、半定量分析(29项研究,49%)或两者联合(16项研究,27%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 各研究使用多种放射性配体,技术方面存在异质性。
- 目前尚无研究采用定量分析方法测量多巴胺转运体丢失。
- 纯定量方法评估多巴胺能传递是否更准确的优越性需进一步明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dopaminergic scintigraphic imaging is a cornerstone to support the diagnosis in dementia with Lewy bodies. To clarify the current state of knowledge on this imaging modality and its impact on clinical diagnosis, we performed an updated systematic review of the literature. METHODS: This systematic review was carried out according to PRISMA guidelines. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases for studies published through June 2022 was performed using the following search algorithm: (a) "Lewy body" [TI] OR "Lewy bodies" [TI] and (b) ("DaTscan" OR "ioflupane" OR "123ip" OR "123?ip" OR "123 ip" OR "123i-FP-CIT" OR "FPCIT" OR "FP-CIT" OR "beta?CIT" OR "beta CIT" OR "CIT?SPECT" OR "CIT SPECT" OR "Dat?scan*" OR "dat scan*" OR "dat?spect*" OR "SPECT"). Risk of bias and applicability concerns of the studies were evaluated using the QUADAS-2 tool. RESULTS: We performed a qualitative analysis of 59 studies. Of the 59 studies, 19 (32%) addressed the diagnostic performance of dopamine transporter imaging, 15 (25%) assessed the identification of dementia with Lewy bodies in the spectrum of Lewy body disease and 18 (31%) investigated the role of functional dopaminergic imaging in distinguishing dementia with Lewy bodies from other dementias. Dopamine transporter loss was correlated with clinical outcomes in 19 studies (32%) and with other functional imaging modalities in 15 studies (25%). Heterogeneous technical aspects were found among the studies through the use of various radioligands, the more prevalent being the [123I]N‑ω‑fluoropropyl‑2β‑carbomethoxy‑3β‑(4‑iodophenyl) nortropane (123I-FP-CIT) in 54 studies (91.5%). Image analysis used visual analysis (9 studies, 15%), semi-quantitative analysis (29 studies, 49%), or a combination of both (16 studies, 27%). CONCLUSION: Our systematic review confirms the major role of dopaminergic scintigraphic imaging in the assessment of dementia with Lewy bodies. Early diagnosis could be facilitated by identifying the prodromes of dementia with Lewy bodies using dopaminergic scintigraphic imaging coupled with emphasis on clinical neuropsychiatric symptoms. Most published studies use a semi-quantitative analytical assessment of tracer uptake, while there are no studies using quantitative analytical methods to measure dopamine transporter loss. The superiority of a purely quantitative approach to assess dopaminergic transmission more accurately needs to be further clarified.
引用
- Jreige M, Kurian GK, Perriraz J, et al. The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review. Eur J Nucl Med Mol Imaging. 2023. PMID: 36920494. doi:10.1007/s00259-023-06154-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。